Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed

27 Apr 2022

On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.

Differentiation — Alkermes stressed the differences between its nemvaleukin and other IL-2 candidates • Source: Alamy

Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed

More from Earnings

More from Business